Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992685 | 0.77 | THRB (0.32) | TSHR | |
| SCHEMBL1064223 | 0.69 | TSHR (0.33) | TSHR | |
| SCHEMBL8186167 | 0.69 | — | — | |
| SCHEMBL20214657 | 0.67 | TSHR (0.31) | TSHR | |
| SCHEMBL8603645 | 0.66 | ALDH1A1 (0.30) | — | |
| SCHEMBL8741526 | 0.65 | TSHR (0.30) | TSHR | |
| SCHEMBL285592 | 0.65 | TSHR (0.30) | TSHR | |
| SCHEMBL634591 | 0.64 | TSHR (0.36) | TSHR | |
| SCHEMBL8328893 | 0.64 | TSHR (0.36) | TSHR | |
| SCHEMBL19930034 | 0.64 | TSHR (0.32) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-02-03 | — | — | US | disclosed |
| US-11174481-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2021-11-16 | — | — | US | disclosed |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-02-04 | — | — | US | disclosed |
| US-20190256849-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2019-08-22 | — | — | US | disclosed |
| EP-3506913-A1 | TARGETING LIGANDS | Arrowhead Pharmaceuticals, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| US-10294474-B2 | Targeting ligands | Arrowhead Pharmaceuticals, Inc. (US) | 2019-05-21 | — | — | US | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180064819-A1 | Targeting Ligands | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2018-03-08 | — | — | US | disclosed |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | BANK OF AMERICA, N.A. | 2017-04-20 | — | — | US | disclosed |
| EP-2475674-B1 | PROBES COMPRISING FLUORESCENT ARTIFICIAL NUCLEOBASES AND USE THEREOF FOR DETECTION OF SINGLE BASE ALTERATION | HUMBOLDT UNIVERSITÄT ZU BERLIN (DE) | 2017-01-25 | — | — | EP | disclosed |
| EP-3040341-A1 | PROBES COMPRISING FLUORESCENT ARTIFICIAL NUCLEOBASES AND USE THEREOF FOR DETECTION OF SINGLE BASE ALTERATION | Humboldt-Universität zu Berlin (DE) | 2016-07-06 | — | — | EP | disclosed |
| US-9206218-B2 | Probes comprising fluorescent artificial nucleobases and use thereof for detection of single base alteration | HUMBOLDT-UNIVERSITAT ZU BERLIN (DE) | 2015-12-08 | — | — | US | disclosed |
| US-20120208178-A1 | PROBES COMPRISING FLUORESCENT ARTIFICIAL NUCLEOBASES AND USE THEREOF FOR DETECTION OF SINGLE BASE ALTERATION | HUMBOLDT-UNIVERSITAT ZU BERLIN (DE) | 2012-08-16 | — | — | US | disclosed |
| EP-2475674-A2 | PROBES COMPRISING FLUORESCENT ARTIFICIAL NUCLEOBASES AND USE THEREOF FOR DETECTION OF SINGLE BASE ALTERATION | Humboldt Universität zu Berlin (DE) | 2012-07-18 | — | — | EP | disclosed |
| WO-2011029835-A2 | PROBES COMPRISING FLUORESCENT ARTIFICIAL NUCLEOBASES AND USE THEREOF FOR DETECTION OF SINGLE BASE ALTERATION | HUMBOLDT-UNIVERSITÄT ZU BERLIN (DE) | 2011-03-17 | — | — | WO | disclosed |
| EP-2292633-A1 | Probes comprising fluorescent artificial nucleobases and use thereof for detection of single base alteration | Humboldt Universität zu Berlin (DE) | 2011-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033817-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | TSHR 2037/4885 |
| US-20180064819-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | TSHR 2037/4885 |
| US-10294474-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | TSHR 2037/4885 |
| US-20190256849-A1 | Targeting Ligands | FABP1, SNRPE, HAVCR2 | TSHR 2037/4885 |
| US-10550386-B2 | Monomers and oligonucleotides comprising cycloaddition adduct(s) | FANCI, PCNA, DNMT1 | TSHR 3635/4885 |
| US-20170107513-A1 | MONOMERS AND OLIGONUCLEOTIDES COMPRISING CYCLOADDITION ADDUCT(S) | FANCI, PCNA, DNMT1 | TSHR 3635/4885 |
| US-11174481-B2 | Targeting ligands | FABP1, SNRPE, HAVCR2 | TSHR 2037/4885 |
| US-20120208178-A1 | PROBES COMPRISING FLUORESCENT ARTIFICIAL NUCLEOBASES AND USE THEREOF FOR DETECTION OF SINGLE BASE ALTERATION | ADAR, CDA, METTL16 | TSHR 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.